Scholarlink

<p>Two hundred and fifty-eight patients with newly diagnosed cGVHD have been enrolled in a multicenter study (NCT02991846). Primary endpoint was failure free survival (FFS); secondary endpoints were ORR at 6 and 12 months after best available therapy (BAT) and OS. Response evaluation was supported by a software (Crosy) collecting cGvHD master data. Software-assisted (SA) response and clinician-based (CB) evaluation, according to NIH criteria, have been performed in parallel at 6 and 12 months. Among 258 patients, 200 needed systemic therapy (ST); 167 were evaluable for response; ORR according to SA was 62% (CR:19%; PR: 43%), and 65% (CR: 23%; PR: 42%) according to the CB evaluation; overall agreement was 66%. In multivariate analysis, only 6-month SA response significantly predicted OS, being more effective in capturing Mixed Responses, compared to CB evaluation. After 12 months 23% of patients were able to stop ST: significantly more patients who maintained ST1 stopped ST (39%) than those who requested a ST1 change (9,5%); (<i>p</i> &lt; 0.001). The 2-year FFS of patients receiving ST was 67%; 2-year OS was 85%: 32 patients (18%) died (30 due to cGVHD progression or causes coexisting with cGvHD). SA evaluation of response in cGVHD is reliable and predicts FFS.</p><p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients

  • 期刊论文

  • 发表日期：

    2026年7月2日

查看全文
  • Attilio Olivieri,
  • Giorgia Mancini,
  • Jacopo Olivieri,
  • Francesco Saraceni,
  • Selene Guerzoni,
  • Irene Federici,
  • Luisa Giaccone,
  • Alessandra Algarotti,
  • Maria Caterina Micò,
  • Giuseppe Milone,
  • Salvatore Leotta,
  • Jacopo Peccatori,
  • Maria Teresa Lupo Stanghellini,
  • Mario Arpinati,
  • Maura Faraci,
  • Fabio Benedetti,
  • Simone Cesaro,
  • Franca Fagioli,
  • Francesco Saglio,
  • Irene Maria Cavattoni,
  • Anna Mele,
  • Chiara Nozzoli,
  • Domenico Russo,
  • Michele Malagola,
  • Carlo Borghero,
  • Daniele Vallisa,
  • Giulia Prunotto,
  • Francesca Patriarca,
  • Antonella Geromin,
  • Edoardo Benedetti,
  • Nicola Mordini,
  • Francesco Merli,
  • Massimo Martino,
  • Francesca Bonifazi

摘要

Two hundred and fifty-eight patients with newly diagnosed cGVHD have been enrolled in a multicenter study (NCT02991846). Primary endpoint was failure free survival (FFS); secondary endpoints were ORR at 6 and 12 months after best available therapy (BAT) and OS. Response evaluation was supported by a software (Crosy) collecting cGvHD master data. Software-assisted (SA) response and clinician-based (CB) evaluation, according to NIH criteria, have been performed in parallel at 6 and 12 months. Among 258 patients, 200 needed systemic therapy (ST); 167 were evaluable for response; ORR according to SA was 62% (CR:19%; PR: 43%), and 65% (CR: 23%; PR: 42%) according to the CB evaluation; overall agreement was 66%. In multivariate analysis, only 6-month SA response significantly predicted OS, being more effective in capturing Mixed Responses, compared to CB evaluation. After 12 months 23% of patients were able to stop ST: significantly more patients who maintained ST1 stopped ST (39%) than those who requested a ST1 change (9,5%); (p < 0.001). The 2-year FFS of patients receiving ST was 67%; 2-year OS was 85%: 32 patients (18%) died (30 due to cGVHD progression or causes coexisting with cGvHD). SA evaluation of response in cGVHD is reliable and predicts FFS.